13 14 15 In the current analysis we included data from the randomized, blinded phase of the trial and the post-trial long term follow-up study, in which participants were no longer randomized.
After completion of the four year follow-up period of the trial phase, a non-randomized, observational post-trial long term follow-up study was implemented, with the goal of extending follow-up for an additional six years (see supplementary file).
For participants in both trials, long term follow-up studies have confirmed active thymopoiesis with a polyclonal and functional T cell receptor repertoire in the majority of patients.
Rightwing hardliners demanded their trial, long-term imprisonment and possible execution.
As part of the Fracture Intervention Trial Long-term Extension (FLEX), women older than 60 with low bone mineral density who had taken alendronate for four or five years were slotted at random into one of two groups.
During a Phase IV trial, long-term safety and effectiveness, side effects that may not have been apparent during Phase III, and optimal usage are evaluated.
Treatment continues in this trial; long-term evaluation allows further assessment of the anticancer activity and tolerability of bosutinib in newly diagnosed CP-CML patients.
The Fracture Intervention Trial Long-term Extension (FLEX) trial shows that there is no difference in hip-fracture risk between past and current users.
The seven articles originated from five different RCTs: in addition to one article for each trial, long-term follow-up outcomes for three of the RCTs [ 11- 13] were reported in two articles [ 14, 15] (Tables 1 and 2).
In addition, for patients presenting with draining fistulas or those using corticosteroids at baseline of the CHARM trial, long-term fistula healing and corticosteroid-free remission were maintained through 4 years of treatment.
